A Phase IV Interventional Safety, Efficacy and Quality of Life Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms ELIGANT
- Sponsors Astellas Pharma
- 20 Jul 2017 Planned End Date changed from 31 Aug 2020 to 1 Aug 2020.
- 20 Jul 2017 Planned primary completion date changed from 31 Aug 2020 to 1 Aug 2020.
- 20 Jul 2017 Status changed from not yet recruiting to recruiting.